JP2007509891A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509891A5
JP2007509891A5 JP2006537197A JP2006537197A JP2007509891A5 JP 2007509891 A5 JP2007509891 A5 JP 2007509891A5 JP 2006537197 A JP2006537197 A JP 2006537197A JP 2006537197 A JP2006537197 A JP 2006537197A JP 2007509891 A5 JP2007509891 A5 JP 2007509891A5
Authority
JP
Japan
Prior art keywords
active ingredient
formulation according
formulation
salt
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006537197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509891A (ja
Filing date
Publication date
Priority claimed from DE2003151301 external-priority patent/DE10351301A1/de
Priority claimed from DE200410014828 external-priority patent/DE102004014828A1/de
Application filed filed Critical
Priority claimed from PCT/EP2004/012230 external-priority patent/WO2005041934A2/de
Publication of JP2007509891A publication Critical patent/JP2007509891A/ja
Publication of JP2007509891A5 publication Critical patent/JP2007509891A5/ja
Pending legal-status Critical Current

Links

JP2006537197A 2003-10-31 2004-10-28 コーティングを有する薬学的活性成分含有製剤 Pending JP2007509891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003151301 DE10351301A1 (de) 2003-10-31 2003-10-31 Retardierte Dosisform aus mehreren Einzeleinheiten
DE200410014828 DE102004014828A1 (de) 2004-03-24 2004-03-24 Pharmazeutische wirkstoffhaltige Formulierung mit Überzug
PCT/EP2004/012230 WO2005041934A2 (de) 2003-10-31 2004-10-28 Pharmazeutische wirkstoffhaltige formulierung mit überzug

Publications (2)

Publication Number Publication Date
JP2007509891A JP2007509891A (ja) 2007-04-19
JP2007509891A5 true JP2007509891A5 (cg-RX-API-DMAC7.html) 2007-12-13

Family

ID=34553325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006537197A Pending JP2007509891A (ja) 2003-10-31 2004-10-28 コーティングを有する薬学的活性成分含有製剤

Country Status (12)

Country Link
US (1) US20080254112A1 (cg-RX-API-DMAC7.html)
EP (1) EP1677766B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509891A (cg-RX-API-DMAC7.html)
AT (1) ATE549015T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285284B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415557A (cg-RX-API-DMAC7.html)
CA (1) CA2543689A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004700A (cg-RX-API-DMAC7.html)
NO (1) NO20062051L (cg-RX-API-DMAC7.html)
NZ (1) NZ547284A (cg-RX-API-DMAC7.html)
RU (1) RU2372893C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005041934A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
CA2642340A1 (en) * 2006-02-24 2007-08-30 Teva Pharmaceutical Industries Ltd. Metoprolol succinate e.r. tablets and methods for their preparation
LT3103448T (lt) * 2006-09-26 2019-10-10 Novartis Ag Farmacinės kompozicijos, apimančios s1p moduliatorių
US8367115B2 (en) 2007-08-27 2013-02-05 Asahi Kasei Chemicals Corporation Process for production of crystalline cellulose and tablets containing granules
JP5204846B2 (ja) * 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対して耐性を有する非オピオイド薬のpH依存性制御放出医薬組成物
CA2699227C (en) * 2007-09-21 2014-12-02 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
EP2231122A1 (en) * 2008-01-10 2010-09-29 Evonik Röhm GmbH Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
MX2010007579A (es) * 2008-01-10 2010-08-03 Evonik Roehm Gmbh Preparacion nutriceutica o farmaceutica revestida con una liberacion de sustancia activa de impulsion mejorada.
RU2011102777A (ru) * 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
US20110311631A1 (en) * 2009-03-18 2011-12-22 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
KR101571198B1 (ko) * 2009-03-18 2015-11-23 에보니크 룀 게엠베하 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물
US8388983B2 (en) * 2009-05-12 2013-03-05 Bpsi Holdings, Llc Film coatings containing fine particle size detackifiers and substrates coated therewith
US8647645B2 (en) * 2009-05-12 2014-02-11 Bpsi Holdings, Llc Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
WO2011136373A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
US20130115292A1 (en) 2010-04-30 2013-05-09 Takeda Pharmaceutical Company Limited Enteric tablet
FR2968559B1 (fr) * 2010-12-14 2012-12-28 Alexandra Fregonese Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique
ES2583132T3 (es) * 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
US20140341984A1 (en) * 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11638759B2 (en) 2019-08-13 2023-05-02 Darlene E. McCord Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
JP7482645B2 (ja) * 2020-02-18 2024-05-14 沢井製薬株式会社 核粒子を含む顆粒の製造方法
US12213993B2 (en) 2021-10-25 2025-02-04 Darlene E. McCord Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis
DE3900811A1 (de) * 1989-01-13 1990-07-19 Kali Chemie Pharma Gmbh Neue arzneiform
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
CA2177769C (en) * 1995-06-07 1999-08-24 Gyanesh P. Khare Particulate compositions that comprise zinc aluminate
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
DE19905906A1 (de) * 1999-02-11 2000-08-17 Basf Ag Verwendung von wasserlöslichen oder wasserdispergierbaren Polyether-haltigen Polymerisaten als Überzugsmittel, Bindemittel und/oder filmbildender Hilfsstoff in pharmazeutischen Darreichungsformen
DE19850238A1 (de) * 1998-10-31 2000-05-04 Triple Trian Beteiligungs Gmbh Verfahren und Vorrichtung zur Kompensation von Elektrosmog
EA200201044A1 (ru) * 2000-03-31 2003-04-24 Нюкомед Аустриа Гмбх Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
RU2323717C2 (ru) * 2001-12-19 2008-05-10 Астразенека Аб Новое пленочное покрытие
EP1651192A1 (en) * 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug

Similar Documents

Publication Publication Date Title
JP2007509891A5 (cg-RX-API-DMAC7.html)
JP6561105B2 (ja) 過活動膀胱の治療のための医薬製剤
RU2372893C2 (ru) Содержащий фармацевтический агент состав с покрытием
JP2016034947A (ja) Jak3インヒビターを含む制御型経口投与製剤
TW200524643A (en) Pantoprazole multiparticulate formulations
JP6759426B2 (ja) Cns化合物の安定化製剤
JP2011503017A (ja) ヒドロモルホン含有徐放性錠剤
FI3324948T3 (fi) Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa
TWI480067B (zh) 經包衣之固體製劑
CN104136004A (zh) 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
JP2023505329A (ja) リオシグアトの放出調節医薬組成物
JP5644495B2 (ja) 被覆固形製剤
US20150366807A1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
US20070196463A1 (en) Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation
WO2017103945A1 (en) Pharmaceutical compositions
WO2014060561A1 (en) Oral pharmaceutical formulations comprising dabigatran
WO2016142821A2 (en) Compositions containing a thrombin inhibitor
JP5664225B2 (ja) 不快味マスキング粒子及びこれを含有する経口製剤
JP2015086194A (ja) ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物
EP3331502A1 (en) Controlled release propiverine formulations
US20070092568A1 (en) Galantamine compositions
WO2011040195A1 (ja) 不快味マスキング粒子及びこれを含有する経口製剤
JPWO2015046383A1 (ja) 原薬含有核の製造方法、原薬含有核、医薬品組成物、及び口腔内崩壊錠
WO2009047800A2 (en) Oral controlled release composition of carvedilol
JP6086520B2 (ja) 薬物高含有固形製剤